The George Washington University is one of approximately 90 sites chosen for the first Phase 3 clinical trial of a COVID-19 vaccine candidate in the US. Watch: https://wjla.com/news/local/500-covid-19-vaccine-volunteers-needed-for-dc-trial
GW Chosen as Site for COVID-19 Phase 3 Vaccine Trial
Latest News
The GW VRU is proud to announce our newest publication to describe the development of a new Na-GST-1/Alhydrogel hookworm vaccine. This study showed promising results and can be read at the link below:
You are invited to attend the first featured presentation in the "State-of-the-Art Topics in Vaccinology" Seminar Series on Tuesday January 28, 2025 at 2 pm. by Dr. Nadine Rouphael, Executive Director of the Hope Clinic at the Emory Vaccine Center.
FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV